My major point of concern would be the final paragraph on page 32 of the FDA (PM) draft. ( https://www.fda.gov/media/140986/download )
"Is an additional clinical trial in the SR-aGVHD population required for confirmation of the effectiveness of the product? What trial design trial would be required to provide evidence of effectiveness in this indication?"
To me, this could be suggesting the need for an additional trial? to further back up the data presented in the one-arm study.
This wouldn't be a decline as such, but it would stretch the time span required for an approval by at least another year.
This should be of no major concern to long term holders.
Bring on Friday! GLTAH
- Forums
- ASX - By Stock
- Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L
My major point of concern would be the final paragraph on page...
-
-
- There are more pages in this discussion • 355 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
0.030(3.19%) |
Mkt cap ! $1.110B |
Open | High | Low | Value | Volume |
94.0¢ | 98.0¢ | 92.0¢ | $3.342M | 3.477M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 33313 | 97.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.5¢ | 73982 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 33313 | 0.970 |
3 | 99109 | 0.965 |
5 | 168086 | 0.960 |
2 | 40000 | 0.955 |
6 | 72924 | 0.950 |
Price($) | Vol. | No. |
---|---|---|
0.975 | 73982 | 2 |
0.980 | 50627 | 6 |
0.985 | 36689 | 4 |
0.990 | 69957 | 4 |
0.995 | 59746 | 2 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO & MD
Anthony Noble
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online